Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-atezolizumab (The Univ. of Alabama at Birmingham)
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
01
Overview
[177Lu]Lu-atezolizumab (The Univ. of Alabama at Birmingham): sourced facts only. name: "These results validate [177Lu]Lu-atezolizumab as a novel PD-L1-targeted radiotherapy which has the potential to improve outcomes of immunotherapy in TNBC patients." [DOI:10.1158/1538-7445.am2026-5819]; target: "These results validate [177Lu]Lu-atezolizumab as a novel PD-L1-targeted radiotherapy which has the potential to improve outcomes of immunotherapy in TNBC patients." [DOI:10.1158/1538-7445.am2026-5819]; developer: "The University of Alabama at Birmingham, Birmingham, AL." [DOI:10.1158/1538-7445.am2026-5819]; modality: "The PD-L1-targeted antibody atezolizumab was radiolabeled with lutetium-177, a cytotoxic radioisotope, to selectively deplete PD-L1+ cells." [DOI:10.1158/1538-7445.am2026-5819]
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on [177Lu]Lu-atezolizumab (The Univ. of Alabama at Birmingham).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-atezolizumab (The Univ. of Alabama at Birmingham).